CT RECIST response, as measured by the change of tumor diameter, can accurately reflect objective response rate for advanced NSCLC patients. However, there exists obvious discordant between CT RECIST response and prognostic indicators. Thus, our study aimed to identify a new CT RECIST response indicator at the early treatment stage to reflect the prognosis more accurately.We studied 916 tumor lesions obtained through deep learning and found that the shape of the lesions was irregular. Besides, we found inconsistencies in CT RECIST responses as measured by changes of tumor diameter and volume at the early treatment stage (response in and ). Moreover, the response in exhibited greater consistency with pathological response and showed a statistical significance with overall survival (P-value=0.0093). In conclusion, our study suggests that response in may serve as a new prognostic indicator for NSCLC patients receiving immunotherapy combined with chemotherapy or chemotherapy alone.
Both the codes for analysis and the data used in this study except CT images and pathological images can be accessed at https://github.com/Josie-xufan/CT-RECIST-Response-Indicator.git.